Developing the next generation of nanomedicines.
Development of cancer therapies based on the unique functions miRNAs.
Drugs against ‘undruggable’ targets: Small Molecule Helix Mimetics.
Fully synthetic therapeutic vaccines against cancer and persistent viral infections.
A new therapeutic approach in immune-oncology, targeting the tumor microenvironment.
Switching from intravenous-to-oral cancer treatment.
Oncolytic adenovirus technologies.
Enabling endosomal escape of macromolecule therapeutics.
Development of angiogenesis inhibitors for the treatment of solid cancers.
Bispecific antibodies which are targeting solid tumors and blood tumors.
Antibody Drug Conjugate Technologies.
Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017
Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures